The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 353:2477-2490 December 8, 2005 Number 23
NextNext

Renal-Cell Carcinoma
Herbert T. Cohen, M.D., and Francis J. McGovern, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
In the United States, renal cancer is the 7th leading malignant condition among men and the 12th among women, accounting for 2.6 percent of all cancers.1 About 2 percent of cases of renal cancer are associated with inherited syndromes. In the United States, 36,160 new cases of renal cancer are predicted to occur in 2005, many of which are being discovered earlier because of the widespread availability of radiographic testing. Nevertheless, 12,660 deaths from the disease are predicted to occur in 2005.1 Renal-cell carcinomas arise from the renal epithelium and account for about 85 percent of renal cancers. A quarter . . . [Full Text of this Article]

Overview

Tumor Types and Molecular Pathogenesis

Conventional or Clear-Cell Renal-Cell Carcinoma

Papillary Renal-Cell Carcinoma

Oncocytoma and Chromophobe Renal-Cell Carcinoma

Collecting-Duct Renal-Cell Carcinoma

Management of Sporadic and Hereditary Renal-Cell Carcinoma

Prognosis

Surgical Treatment

Radical Nephrectomy

Surgery for Metastatic Disease

Nephron-Sparing Partial Nephrectomy

Laparoscopic Nephrectomy

Percutaneous Ablative Approaches

Medical Treatment

Chemotherapy

Immunomodulatory Therapies

            Interferon Alfa

            Interleukin-2

Adjuvant Therapy

Evolving Therapies

Stem-Cell Transplantation

Tumor Vaccines

Target Antigens

Therapies Targeting VEGF and TGF-{alpha} Pathways

            VEGF-Pathway Components as Molecular Targets

            TGF-{alpha}–Pathway Components as Molecular Targets

            Other Approaches

Summary and Prospects for the Future


Source Information

From the Renal and Hematology–Oncology Sections, Departments of Medicine and Pathology, Boston University School of Medicine (H.T.C.); and the Department of Urology, Massachusetts General Hospital and Harvard Medical School (F.J.M.) — all in Boston.

Address reprint requests to Dr. Cohen at the Department of Medicine, Renal Section, Boston University School of Medicine, Evans Biomedical Research Center, 650 Albany St., Rm. X-535, Boston, MA 02118, or at htcohen@bu.edu.


Related Letters:

Renal-Cell Carcinoma
Doh L., Curtis A. E., Teh B. S., Vincenzi B., Santini D., Tonini G., Cohen H. T., McGovern F. J.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1095-1096, Mar 9, 2006. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.